Clinical Trials Logo

Filter by:
NCT ID: NCT05403450 Active, not recruiting - Clinical trials for Relapsed/Refractory Peripheral T-cell Lymphoma

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Start date: June 23, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2.

NCT ID: NCT05402371 Active, not recruiting - NAFLD Clinical Trials

A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis

ASCEND
Start date: October 15, 2022
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, parallel-dosing, multi-center study to evaluate the efficacy and safety of Rencofilstat as evidenced by histopathological improvements in fibrosis in adult NASH subjects with F2 or F3 fibrosis (NASH CRN system). Antifibrotic biomarker activity will be evaluated on an exploratory basis.

NCT ID: NCT05400863 Active, not recruiting - Pre Diabetes Clinical Trials

Effect of NNS on Metformin/GDF15, Pilot

Start date: April 21, 2022
Phase: N/A
Study type: Interventional

Metformin use for diabetes has the benefit of causing weight loss in some. The investigators in a preclinical trial, demonstrated that mice consuming non-nutritive sweetened (NNS) drinks had worse glucose improvements and weight loss than mice consuming sugar drinks or water. This study will conduct a pilot to determine if this translates into pediatric clinical practice. The hypothesis is that NNS drinks impair metformin-induced satiation, weight loss, and glucose tolerance.

NCT ID: NCT05400109 Active, not recruiting - Clinical trials for Non Hodgkin Lymphoma

Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas

Start date: April 26, 2023
Phase: Phase 1
Study type: Interventional

This treatment uses T cells already present in the participant's body that have been modified outside of the body by a lentivirus and then returned by an infusion to target the cancer. Lentivirus is a family of viruses that can be used by scientists to alter cells. The specific type of cells that will be used is called UF-KURE19 chimeric antigen receptor T cells (CAR-T cells). The CAR-T cells that will be reinfused into the body are modified using a lentivirus that is no longer active. The investigators are evaluating UF-KURE19 because it uses a process that is shorter than other approved CAR-T cells. While the shorter manufacture time can be an advantage, the safety of this approach has not been demonstrated.

NCT ID: NCT05399004 Active, not recruiting - Bladder Carcinoma Clinical Trials

Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer

Start date: September 3, 2019
Phase:
Study type: Observational

This study evaluates the general physical, emotional, and sexual function in women undergoing a radical cystectomy for bladder cancer. A radical cystectomy is a surgical procedure that involves the removal of the bladder, uterus, ovaries, fallopian tubes, and part of the vagina. This may affect sexual function in women. This study seeks to understand how radical cystectomy alters sexual function and well-being, and what factors may affect this change.

NCT ID: NCT05398796 Active, not recruiting - Clinical trials for Nipah Virus Infection

Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults

Start date: July 11, 2022
Phase: Phase 1
Study type: Interventional

Background: Nipah virus (NiV) is transmitted from animals to humans, from humans to humans, and through contaminated food. Infected people may have a cough and trouble breathing. Some people may develop serious symptoms, such as brain inflammation, that can lead to death. There are no drugs or vaccines to treat or prevent NiV infection. Objective: To test the safety of an experimental vaccine (mRNA-1215) for NiV. Researchers will also evaluate how participants bodies respond to the vaccine. Eligibility: Healthy, nonpregnant adults aged 18 to 60 years. Design: Participants will visit the NIH clinic 13 to 15 times over 14 to 16 months. Participants will get 2 doses of the experimental vaccine during this study at either 1 month or 4 months apart. The vaccine will be given as a shot into the muscle of the upper arm. Participants will stay in the clinic at least 30 minutes after each vaccination. Participants will be given a diary card and a thermometer. They will record their temperature and any other symptoms for 7 days after each vaccination. During each follow-up visit, 3 to 14 tubes of blood will be drawn for research. Participants may undergo an optional procedure called apheresis. A needle will be placed into a vein in each arm. Blood will be removed through one needle. The blood will pass through a machine that separates some of the blood cells. The rest of the blood will return to the body through the other needle. The study vaccine cannot cause NiV infection.

NCT ID: NCT05398744 Active, not recruiting - Clinical trials for Orthotopic Heart Transplant

Motivational Interviewing and Group Heart Transplant Exercise and Education: A Pilot Study

MIGHTEE
Start date: July 13, 2022
Phase: N/A
Study type: Interventional

The aim of this 16-week group aerobic training program, delivered remotely via video-conferencing, is to assess program feasibility, and determine if program increases physical activity in adolescents after heart transplant.

NCT ID: NCT05398445 Active, not recruiting - Atopic Dermatitis Clinical Trials

A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

ROCKET-Ignite
Start date: May 31, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.

NCT ID: NCT05398172 Active, not recruiting - Vaginal Atrophy Clinical Trials

Clinical Evaluation of Fractional Bi-Polar Radio-Frequency for Symptoms of Vulvovaginal Atrophy

Start date: August 10, 2021
Phase: N/A
Study type: Interventional

Prospective, one arm, baseline-controlled At least 30 healthy adult female volunteers, from 2 investigational sites seeking treatment for Symptoms of Vulvovaginal Atrophy Eligible subjects will receive 3 treatments 4 weeks apart with the MorpheusV Applicator according to the study protocol The subject will return for 3 follow up visits: 3 months follow up (3M FU), 6 months follow up (6M FU), 12months follow up (12M FU) after the treatment. Total expected study duration is approximately 12 months.

NCT ID: NCT05397912 Active, not recruiting - Infertility, Female Clinical Trials

Uterine Elastography: a Potential Predictor of Embryo Transfer Success

Start date: June 15, 2022
Phase:
Study type: Observational

To determine if the mean elasticity value (measured in kilopascals, kPa) of a patient's endometrium, myometrium and cervix in a sonographically normal appearing uterus predict frozen embryo transfer (FET) success and long term reproductive outcomes when measured the day prior to FET.